New Ray Medicine International Holding Limited (NEW RAY MEDIC) aktie

New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People's Republic of China. Its pharmaceutical products include levocarnitine injection for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, and parenteral nutrition; thoymosin a1 for injection to treat hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor relating hepatitis B, and chronic hepatitis C; and cefamandole nafate, ceftizoxime sodium, and isepamicin sulfate injection for the treatment of respiratory tract infections, genitourinary system infections, urinary tract infections, intra-abdominal infections, bone, joint infections, and septicemia. The company also offers alanyl glutamine for injection that is indicated for catabolism and hypermetabolism; cefixime dispersible tablets to treat infections caused by streptococcus and pneumococcus, chronic bronchitis, acute bronchitis with bacterial infection, pneumonia, pyelonephritis, cystitis, gonococcal urethritis, and acute bacterial infection of the biliary tract system; and clostridium butyricum capsule for diarrhea and digestive system relevant illness. Further, it provides marketing and promotion services. New Ray Medicine International Holding Limited was founded in 2001 and is headquartered in Hangzhou, the People's Republic of China.